Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Assets: 2018-2025

Historic Non-Current Assets for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $367,017.

  • China SXT Pharmaceuticals' Non-Current Assets fell 96.55% to $310,889 in Q3 2025 from the same period last year, while for Sep 2025 it was $310,889, marking a year-over-year decrease of 96.55%. This contributed to the annual value of $367,017 for FY2025, which is 95.87% down from last year.
  • According to the latest figures from FY2025, China SXT Pharmaceuticals' Non-Current Assets is $367,017, which was down 95.87% from $8.9 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Non-Current Assets registered a high of $11.3 million during FY2021, and its lowest value of $367,017 during FY2025.
  • Its 3-year average for Non-Current Assets is $6.4 million, with a median of $8.9 million in 2024.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 447.67% in 2021, then slumped by 95.87% in 2025.
  • China SXT Pharmaceuticals' Non-Current Assets (Yearly) stood at $11.3 million in 2021, then decreased by 1.94% to $11.1 million in 2022, then decreased by 9.57% to $10.0 million in 2023, then decreased by 11.35% to $8.9 million in 2024, then slumped by 95.87% to $367,017 in 2025.